PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Capricor Therapeutics, Inc. (CAPR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US14070B3096

CUSIP

14070B309

Sector

Healthcare

IPO Date

Feb 13, 2007

Highlights

Market Cap

$725.24M

EPS (TTM)

-$1.05

Total Revenue (TTM)

$11.14M

Gross Profit (TTM)

$10.45M

EBITDA (TTM)

-$33.82M

Year Range

$3.52 - $23.40

Target Price

$41.29

Short %

19.13%

Short Ratio

9.61

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
CAPR vs. SPY
Popular comparisons:
CAPR vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Capricor Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%100.00%200.00%300.00%400.00%SeptemberOctoberNovemberDecember2025February
293.33%
9.03%
CAPR (Capricor Therapeutics, Inc.)
Benchmark (^GSPC)

Returns By Period

Capricor Therapeutics, Inc. had a return of 15.58% year-to-date (YTD) and 341.83% in the last 12 months. Over the past 10 years, Capricor Therapeutics, Inc. had an annualized return of -12.06%, while the S&P 500 had an annualized return of 11.26%, indicating that Capricor Therapeutics, Inc. did not perform as well as the benchmark.


CAPR

YTD

15.58%

1M

16.42%

6M

292.86%

1Y

341.83%

5Y*

63.46%

10Y*

-12.06%

^GSPC (Benchmark)

YTD

3.96%

1M

1.97%

6M

9.03%

1Y

22.16%

5Y*

12.60%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of CAPR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20258.99%15.58%
2024-17.38%3.96%61.67%-22.39%7.78%-16.02%-14.88%12.56%232.82%32.15%-5.42%-27.41%182.21%
20239.33%7.82%-7.25%-7.82%16.45%5.52%-7.95%47.27%-47.22%-17.54%5.32%64.65%26.68%
202221.84%13.45%-15.31%-7.58%14.51%-3.86%32.09%26.25%3.09%-7.33%-19.60%-13.65%31.74%
202191.84%-6.69%-23.78%-1.07%-18.14%35.36%-14.81%14.65%-19.76%-7.46%-9.41%-13.06%-14.58%
202019.53%-22.88%1.69%483.33%-33.71%-0.86%73.04%-24.25%-12.94%-26.48%8.81%-18.33%167.97%
201924.02%-13.55%6.07%3.09%-34.93%6.14%32.53%-45.91%55.46%-30.81%-39.45%-17.42%-68.78%
201826.58%-9.00%-25.27%1.47%-3.62%0.75%-12.69%3.42%-13.22%-11.43%-16.99%-46.89%-74.05%
2017-8.27%18.85%16.55%-7.69%-73.88%1.83%27.73%-3.77%197.06%-18.15%-24.19%-15.96%-40.60%
2016-13.13%-8.03%3.44%55.12%-19.04%23.82%-6.33%-1.08%-11.40%-10.26%8.25%-15.56%-13.46%
201573.33%-10.46%48.11%-30.71%-1.21%-14.41%-8.91%3.48%-14.92%-2.22%6.57%-27.17%-18.04%
2014315.38%-13.33%-27.35%-41.29%-3.81%-8.33%-12.50%13.77%-12.10%6.49%-4.39%-4.34%15.38%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 95, CAPR is among the top 5% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of CAPR is 9595
Overall Rank
The Sharpe Ratio Rank of CAPR is 9797
Sharpe Ratio Rank
The Sortino Ratio Rank of CAPR is 9595
Sortino Ratio Rank
The Omega Ratio Rank of CAPR is 9494
Omega Ratio Rank
The Calmar Ratio Rank of CAPR is 9595
Calmar Ratio Rank
The Martin Ratio Rank of CAPR is 9393
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Capricor Therapeutics, Inc. (CAPR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for CAPR, currently valued at 2.83, compared to the broader market-2.000.002.004.002.831.83
The chart of Sortino ratio for CAPR, currently valued at 3.81, compared to the broader market-6.00-4.00-2.000.002.004.006.003.812.47
The chart of Omega ratio for CAPR, currently valued at 1.49, compared to the broader market0.501.001.502.001.491.33
The chart of Calmar ratio for CAPR, currently valued at 3.17, compared to the broader market0.002.004.006.003.172.76
The chart of Martin ratio for CAPR, currently valued at 11.55, compared to the broader market-10.000.0010.0020.0030.0011.5511.27
CAPR
^GSPC

The current Capricor Therapeutics, Inc. Sharpe ratio is 2.83. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Capricor Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.002.004.006.00SeptemberOctoberNovemberDecember2025February
2.83
1.83
CAPR (Capricor Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Capricor Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-99.51%
-0.07%
CAPR (Capricor Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Capricor Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Capricor Therapeutics, Inc. was 99.97%, occurring on Mar 10, 2020. The portfolio has not yet recovered.

The current Capricor Therapeutics, Inc. drawdown is 99.51%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.97%Nov 19, 20072930Mar 10, 2020
-56.19%Apr 9, 20074Jul 27, 20072Sep 18, 20076
-11.54%Oct 25, 20073Oct 30, 20076Nov 16, 20079
-2.33%Sep 27, 20071Sep 27, 20072Oct 5, 20073
-2.22%Oct 11, 20071Oct 11, 20072Oct 24, 20073

Volatility

Volatility Chart

The current Capricor Therapeutics, Inc. volatility is 16.95%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%SeptemberOctoberNovemberDecember2025February
16.95%
3.21%
CAPR (Capricor Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Capricor Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Capricor Therapeutics, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab